AR032756A1 - Metodo de tratamiento para inhibir el progreso o para aliviar una condicion que se alivia por un antagonista de 5-ht3 o del receptor nicotinico neuronal y uso de 1-amino-alquilciclohexanos - Google Patents
Metodo de tratamiento para inhibir el progreso o para aliviar una condicion que se alivia por un antagonista de 5-ht3 o del receptor nicotinico neuronal y uso de 1-amino-alquilciclohexanosInfo
- Publication number
- AR032756A1 AR032756A1 ARP010102918A ARP010102918A AR032756A1 AR 032756 A1 AR032756 A1 AR 032756A1 AR P010102918 A ARP010102918 A AR P010102918A AR P010102918 A ARP010102918 A AR P010102918A AR 032756 A1 AR032756 A1 AR 032756A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- condition
- group
- inhibit
- antagonist
- Prior art date
Links
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000001537 neural effect Effects 0.000 title abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 230000003287 optical effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940113081 5 Hydroxytryptamine 3 receptor antagonist Drugs 0.000 abstract 1
- 102000035037 5-HT3 receptors Human genes 0.000 abstract 1
- 108091005477 5-HT3 receptors Proteins 0.000 abstract 1
- 208000007848 Alcoholism Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000027559 Appetite disease Diseases 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000000323 Tourette Syndrome Diseases 0.000 abstract 1
- 208000016620 Tourette disease Diseases 0.000 abstract 1
- 206010044565 Tremor Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 206010001584 alcohol abuse Diseases 0.000 abstract 1
- 208000025746 alcohol use disease Diseases 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000004075 alteration Effects 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- -1 hydrate Chemical class 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 230000000862 serotonergic effect Effects 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Método para tratar a un animal vivo para inhibir el progreso o para aliviar una condicion que se alivia por un antagonista de 5-HT3 o del receptor nicotínico neuronal, que comprende el paso de administrar a dicho animal vivo una cantidad de un compuesto 1-aminoalquilciclohexano que se selecciona entre el grupo que consiste en aquéllos que tienen la formula (1), donde R* es-(CH2)n-(CR6R7)m-NR8R9, donde n + m = 0, 1, o 2, donde desde R1 hasta R7 se seleccionan independientemente entre el grupo que consiste en hidrogeno y alquilo inferior C1-6, donde R8 y R9 se seleccionan independientemente entre el grupo que consiste en hidrogeno y alquilo inferior C1-6 o juntos representan alquileno inferior -(CH2)x-donde x es 2 a 5, inclusive, e isomeros opticos, enantiomeros, hidrato, y sales aceptables para uso farmacéutico de los mismos, que es efectivo para dicho proposito. Estos 1-aminoalquilciclohexanos son antagonistas del receptor nicotínico y 5-HT3 sistemáticamente activos y son utiles para inhibir el progreso o para aliviar condiciones que se producen por alteraciones de la transmision serotoninérgica o nicotinérgica, con lo cual despliegan un amplio rango de utilidad para el tratamiento de trastornos del sistema nervioso central. Preferiblemente, la condicion alivianada o inhibida se selecciona entre el grupo que consiste en emesis, trastornos de ansiedad, esquizofrenia, trastornos por abuso de drogas y alcohol, trastornos depresivos, trastornos cognitivos, enfermedad de Alzheimer, temblor cerebeloso, enfermedad de Parkinson, mal de Tourette, y trastornos del apetito. Uso de 1-amino-alquilciclohexanos incluyendo sus isomeros opticos, enantiomeros, hidratos, y sales aceptables para uso farmacéutico de los mismos, en la fabricacion de un medicamento para tratar un animal vivo para inhibir la progresion de o aliviar una condicion que se alivia mediante un antagonista del receptor 5-HT3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59710200A | 2000-06-20 | 2000-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032756A1 true AR032756A1 (es) | 2003-11-26 |
Family
ID=24390098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010102918A AR032756A1 (es) | 2000-06-20 | 2001-06-19 | Metodo de tratamiento para inhibir el progreso o para aliviar una condicion que se alivia por un antagonista de 5-ht3 o del receptor nicotinico neuronal y uso de 1-amino-alquilciclohexanos |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20070105961A1 (es) |
| EP (2) | EP2277850A1 (es) |
| JP (1) | JP4159351B2 (es) |
| KR (1) | KR100570374B1 (es) |
| CN (1) | CN1307147C (es) |
| AR (1) | AR032756A1 (es) |
| AU (2) | AU8186101A (es) |
| CA (1) | CA2410852C (es) |
| CZ (1) | CZ2003497A3 (es) |
| EA (1) | EA006067B1 (es) |
| GE (1) | GEP20053431B (es) |
| HU (1) | HUP0301551A3 (es) |
| IL (2) | IL153480A0 (es) |
| MX (1) | MXPA02012244A (es) |
| NO (1) | NO329491B1 (es) |
| PL (1) | PL359583A1 (es) |
| TW (1) | TW593223B (es) |
| UA (1) | UA74194C2 (es) |
| WO (1) | WO2001098253A2 (es) |
| ZA (1) | ZA200104187B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0000540D0 (sv) | 2000-02-18 | 2000-02-18 | Astrazeneca Ab | New compounds |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| TW200306189A (en) | 2002-03-21 | 2003-11-16 | Merz Pharma Gmbh & Co Kgaa | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| AU2003274353B2 (en) * | 2002-10-24 | 2007-04-05 | Merz Pharma Gmbh & Co. Kgaa | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors |
| RS20050851A (sr) | 2003-05-27 | 2008-04-04 | Forest Laboratories Inc., | Kombinacija antagonista nmda receptora i selektivnog inhibitora ponovnog preuzimanja serotonina za lečenje depresije i drugih poremećaja raspoloženja |
| AU2004258751C1 (en) * | 2003-07-28 | 2008-07-17 | Merz Pharma Gmbh & Co. Kgaa | The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity |
| AR046314A1 (es) * | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
| TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
| EP2601937A1 (en) * | 2004-06-17 | 2013-06-12 | Merz Pharma GmbH & Co. KGaA | Drinkable immediate release tablet made with direct compression of memantine or neramexane |
| AU2005325292A1 (en) * | 2005-01-18 | 2006-07-27 | University Of Florida | Compositions and methods for inhibiting pain |
| AU2009316557B2 (en) | 2008-11-19 | 2015-08-27 | Envivo Pharmaceuticals, Inc. | Treatment of cognitive disorders with (R)-7-chloro-N-(quinuclidin-3-yl) benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof |
| TWI432188B (zh) * | 2008-12-19 | 2014-04-01 | Merz Pharma Gmbh & Co Kgaa | 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類 |
| AU2009328497A1 (en) | 2008-12-19 | 2010-06-24 | Merz Pharma Gmbh & Co. Kgaa | 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases |
| CA2799744C (en) | 2010-05-17 | 2020-01-28 | Envivo Pharmaceuticals, Inc. | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate |
| US9585877B2 (en) | 2012-05-08 | 2017-03-07 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9411955D0 (en) * | 1994-06-15 | 1994-08-03 | Merck Sharp & Dohme | Therapeutic agents |
| US5886051A (en) * | 1995-11-08 | 1999-03-23 | University Of Florida Research Foundation, Inc. | Methods and compositions for the treatment of neurodegeneration |
| ZA9610738B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| US5728728A (en) * | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
| US6436946B1 (en) * | 1997-05-02 | 2002-08-20 | Morris A. Mann | Xanthine-containing compositions for oral administration and uses related thereto |
| US5866585A (en) * | 1997-05-22 | 1999-02-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia using NMDA receptor antagonists |
| US6071966A (en) * | 1997-06-30 | 2000-06-06 | Merz + Co. Gmbh & Co. | 1-amino-alkylcyclohexane NMDA receptor antagonists |
| ES2200358T3 (es) * | 1997-06-30 | 2004-03-01 | MERZ PHARMA GMBH & CO. KGAA | 1-amino-alquilciclohexanos antagonistas del receptor de nmda. |
| AR016212A1 (es) * | 1998-04-28 | 2001-06-20 | Astra Ab | Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas |
| US6139861A (en) * | 1999-01-14 | 2000-10-31 | Friedman; Mark | Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm |
| US6828462B2 (en) * | 2001-11-07 | 2004-12-07 | Merz Pharma Gmbh & Co. Kgaa | Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
-
2001
- 2001-05-14 TW TW090111488A patent/TW593223B/zh not_active IP Right Cessation
- 2001-05-22 ZA ZA200104187A patent/ZA200104187B/xx unknown
- 2001-06-19 AR ARP010102918A patent/AR032756A1/es unknown
- 2001-06-19 EA EA200300040A patent/EA006067B1/ru not_active IP Right Cessation
- 2001-06-19 AU AU8186101A patent/AU8186101A/xx active Pending
- 2001-06-19 JP JP2002504209A patent/JP4159351B2/ja not_active Expired - Fee Related
- 2001-06-19 KR KR1020027017329A patent/KR100570374B1/ko not_active Expired - Fee Related
- 2001-06-19 EP EP10184507A patent/EP2277850A1/en not_active Withdrawn
- 2001-06-19 HU HU0301551A patent/HUP0301551A3/hu unknown
- 2001-06-19 WO PCT/EP2001/006964 patent/WO2001098253A2/en not_active Ceased
- 2001-06-19 AU AU2001281861A patent/AU2001281861B2/en not_active Ceased
- 2001-06-19 CN CNB01811413XA patent/CN1307147C/zh not_active Expired - Fee Related
- 2001-06-19 CA CA002410852A patent/CA2410852C/en not_active Expired - Fee Related
- 2001-06-19 IL IL15348001A patent/IL153480A0/xx active IP Right Grant
- 2001-06-19 GE GE5059A patent/GEP20053431B/en unknown
- 2001-06-19 PL PL01359583A patent/PL359583A1/xx not_active Application Discontinuation
- 2001-06-19 MX MXPA02012244A patent/MXPA02012244A/es active IP Right Grant
- 2001-06-19 EP EP01960342A patent/EP1303477A2/en not_active Withdrawn
- 2001-06-19 UA UA2003010457A patent/UA74194C2/uk unknown
- 2001-06-19 CZ CZ2003497A patent/CZ2003497A3/cs unknown
-
2002
- 2002-12-16 IL IL153480A patent/IL153480A/en not_active IP Right Cessation
- 2002-12-19 NO NO20026103A patent/NO329491B1/no not_active IP Right Cessation
-
2006
- 2006-12-21 US US11/643,129 patent/US20070105961A1/en not_active Abandoned
-
2010
- 2010-07-26 US US12/804,610 patent/US20100298442A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NO20026103D0 (no) | 2002-12-19 |
| WO2001098253A3 (en) | 2002-04-25 |
| IL153480A (en) | 2007-08-19 |
| GEP20053431B (en) | 2005-01-25 |
| HUP0301551A2 (hu) | 2003-11-28 |
| PL359583A1 (en) | 2004-08-23 |
| TW593223B (en) | 2004-06-21 |
| CZ2003497A3 (cs) | 2004-08-18 |
| WO2001098253A2 (en) | 2001-12-27 |
| AU8186101A (en) | 2002-01-02 |
| CN1620419A (zh) | 2005-05-25 |
| JP2004501130A (ja) | 2004-01-15 |
| US20070105961A1 (en) | 2007-05-10 |
| KR100570374B1 (ko) | 2006-04-24 |
| EP2277850A1 (en) | 2011-01-26 |
| MXPA02012244A (es) | 2004-09-06 |
| EA006067B1 (ru) | 2005-08-25 |
| HK1076276A1 (en) | 2006-01-13 |
| HUP0301551A3 (en) | 2005-04-28 |
| EA200300040A1 (ru) | 2003-06-26 |
| KR20030053475A (ko) | 2003-06-28 |
| JP4159351B2 (ja) | 2008-10-01 |
| CA2410852A1 (en) | 2001-12-27 |
| NO329491B1 (no) | 2010-10-25 |
| UA74194C2 (uk) | 2005-11-15 |
| EP1303477A2 (en) | 2003-04-23 |
| AU2001281861B2 (en) | 2006-08-17 |
| ZA200104187B (en) | 2002-11-22 |
| NO20026103L (no) | 2003-02-19 |
| CA2410852C (en) | 2007-04-24 |
| IL153480A0 (en) | 2003-07-06 |
| CN1307147C (zh) | 2007-03-28 |
| US20100298442A1 (en) | 2010-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032756A1 (es) | Metodo de tratamiento para inhibir el progreso o para aliviar una condicion que se alivia por un antagonista de 5-ht3 o del receptor nicotinico neuronal y uso de 1-amino-alquilciclohexanos | |
| SE0202134D0 (sv) | Therapeutic agents | |
| ATE509929T1 (de) | Substituierte tricyclische gamma-carbolineals serotonin-rezeptor-agonisten und antagonisten | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| HRP20110015T1 (hr) | DERIVATI IMIDAZO[1,2-a]PIRIDIN-2-KARBOKSAMIDA, NJIHOVO DOBIVANJE I NJIHOVA UPOTREBA U TERAPIJI | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| MA26904A1 (fr) | Aminoalkyl 1-lactames substituees et leur utilisation en tant qu'antagonistes du recepteur muscarinique. | |
| SE0104334D0 (sv) | Therapeutic agents | |
| AR030507A1 (es) | Compuesto de pirazolopiridina y los usos farmaceuticos del mismo | |
| BRPI0415657A (pt) | derivados de alcanamina de diidrobenzofuranila como agonistas de 5ht2c | |
| DE602004020994D1 (de) | Piperidinverbindungen und pharmazeutische zusammensetzungen, die diese enthalten | |
| PL361282A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| UY30377A1 (es) | Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa | |
| ECSP088967A (es) | Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| ECSP056192A (es) | 3-fluoro-piperidinas como antagonistas de nmda/nr2b | |
| PE20030718A1 (es) | Lactamas como antagonistas de taquiquininas | |
| PT757685E (pt) | Novas amidas ciclicas como incrementadores de libertacao de neurotransmissores | |
| UY26919A1 (es) | Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1 | |
| PE20191646A1 (es) | Derivados pirazol [1,5-a] pirimidina sustituidos con aliciclicos farmacologicamente activos | |
| AR056943A1 (es) | DERIVADOS DE AMIDAS, ISoMEROS DE LOS MISMOS O LAS SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS COMO EL ANTAGONISTA DEL RECEPTOR VANILOIDE Y LAS COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS MISMOS | |
| MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
| UY28815A1 (es) | Agentes terapéuticos | |
| RU2443697C1 (ru) | Замещенные метил-амины, антагонисты серотониновых 5-ht6 рецепторов, способы получения и применения | |
| AR028805A1 (es) | Nuevas piperidinas 4-sustituidas, asi como sus sales farmaceuticas con acidos inoranicos y organicos, obtenidas como mezclas racemicas y como enantiomeros puros, mezclados con excipientes para administracion oral, parental y topica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |